1. Home
  2. ZCMD vs NXL Comparison

ZCMD vs NXL Comparison

Compare ZCMD & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

N/A

Current Price

$0.11

Market Cap

7.9M

Sector

Real Estate

ML Signal

N/A

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

N/A

Current Price

$0.61

Market Cap

7.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZCMD
NXL
Founded
2012
2010
Country
China
United States
Employees
N/A
8
Industry
Other Consumer Services
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
ZCMD
NXL
Price
$0.11
$0.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
7.1M
754.0K
Earning Date
04-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$15.52
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.08
$0.31
52 Week High
$2.29
$2.00

Technical Indicators

Market Signals
Indicator
ZCMD
NXL
Relative Strength Index (RSI) 12.24 78.78
Support Level N/A $0.35
Resistance Level $0.71 $0.69
Average True Range (ATR) 0.25 0.06
MACD -0.16 0.03
Stochastic Oscillator 1.49 98.48

Price Performance

Historical Comparison
ZCMD
NXL

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: